Optimization of the use of integrase inhibitors : contribution of pharmacogenetic

Study Objective

The aims of this study are :

1/ to identify genetic polymorphisms in genes implicated in the pharmacokinetic of Raltegravir
2/ to analyse the impact of these polymorphisms on intracellular concentration of this drug
3/ to study the influence of genetic and/or pharmacokinetic variability on drug efficacy (by monitoring of viral load and CD4 count) and on potential side effects

Participation conditions

Inclusion criteria : Every adult person treated for at least 4 months by Raltegravir (Isentress) can be included in this study.

Exclusion criteria : Concomitant treatment for hepatitis B or C infection

Centre Hospitalier de Luxembourg